Cyrus Biotechnology

Seattle, United States Founded: 2014 • Age: 12 yrs
Cloud-based protein-modeling software is developed for drug discovery.
Request Access

About Cyrus Biotechnology

Cyrus Biotechnology is a company based in Seattle (United States) founded in 2014.. Cyrus Biotechnology has raised $31.99 million across 11 funding rounds from investors including HHS, Orbimed and Trinity Ventures. The company has 23 employees as of December 31, 2022. Cyrus Biotechnology has completed 1 acquisition, including Orthogonal Biologics. Cyrus Biotechnology offers products and services including IdeS, IL-22 Variant, and sACE2.v2-Fc. Cyrus Biotechnology operates in a competitive market with competitors including Vividion Therapeutics, Seer, Biognosys, ProteinSimple and NiKang Therapeutics, among others.

  • Headquarter Seattle, United States
  • Employees 23 as on 31 Dec, 2022
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Cyrus Biotechnology Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $31.99 M (USD)

    in 11 rounds

  • Latest Funding Round
    $300 K (USD), Grant

    Dec 20, 2024

  • Investors
    HHS

    & 10 more

  • Employee Count
    23

    as on Dec 31, 2022

  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Cyrus Biotechnology

Cyrus Biotechnology offers a comprehensive portfolio of products and services, including IdeS, IL-22 Variant, and sACE2.v2-Fc. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Protein for IgG depletion in autoimmune diseases.

Fusion protein for gastrointestinal and metabolic conditions.

Candidate for COVID-19 prophylaxis in immunocompromised individuals.

People of Cyrus Biotechnology
Headcount 10-50
Employee Profiles 16
Board Members and Advisors 5
Employee Profiles
People
Andy Jerome
Program & Business Development Manager
People
Lucas Nivon
CEO
People
Brandon Frenz
Scientific Software Developer
People
Max Sauer
Scientist III

Unlock access to complete

Board Members and Advisors
people
David Baker
Scientific Co-Founder & Advisor
people
Eric Bell
Board Member
people
Chad Waite
Board Member
people
Will Chen
Scientific Advisor

Unlock access to complete

Funding Insights of Cyrus Biotechnology

Cyrus Biotechnology has successfully raised a total of $31.99M across 11 strategic funding rounds. The most recent funding activity was a Grant round of $300 thousand completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 11
  • Last Round Grant — $300,000
  • First Round

    (06 May 2015)

  • Investors Count 11
Date Amount Transaction Name Valuation Lead Investors Investors
Dec, 2024 Amount Grant - Cyrus Biotechnology Valuation

investors

HHS
Sep, 2024 Amount Grant - Cyrus Biotechnology Valuation

investors

HHS
Feb, 2024 Amount Series B - Cyrus Biotechnology Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Cyrus Biotechnology

Cyrus Biotechnology has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Orbimed and Trinity Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
Founded Year Domain Location
Venture capital firm investing in early-stage technology and real estate companies.
Founded Year Domain Location
Agent Capital is focused on healthcare venture capital investments.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Cyrus Biotechnology

Cyrus Biotechnology has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Orthogonal Biologics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Protein drug manufacturing and research services are provided.
2020
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Cyrus Biotechnology

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Cyrus Biotechnology Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Cyrus Biotechnology

Cyrus Biotechnology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Vividion Therapeutics, Seer, Biognosys, ProteinSimple and NiKang Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developing novel drugs based on a proteome-wide ligand and target discovery platform
domain founded_year HQ Location
Proteomics platform developed for early cancer and neurological disease detection.
domain founded_year HQ Location
Proteomics services are delivered via discovery and targeted platforms.
domain founded_year HQ Location
Provider tools to help researchers with protein analysis
domain founded_year HQ Location
Small molecule oncology therapeutics are developed for cancer treatment.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Cyrus Biotechnology

Frequently Asked Questions about Cyrus Biotechnology

When was Cyrus Biotechnology founded?

Cyrus Biotechnology was founded in 2014 and raised its 1st funding round 1 year after it was founded.

Where is Cyrus Biotechnology located?

Cyrus Biotechnology is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.

Is Cyrus Biotechnology a funded company?

Cyrus Biotechnology is a funded company, having raised a total of $31.99M across 11 funding rounds to date. The company's 1st funding round was a Series B of $2.69M, raised on May 06, 2015.

How many employees does Cyrus Biotechnology have?

As of Dec 31, 2022, the latest employee count at Cyrus Biotechnology is 23.

What does Cyrus Biotechnology do?

Cyrus Biotechnology was founded in 2014 in Seattle, United States, within the biotechnology sector. Cloud-based software for protein modeling in drug discovery is provided. The primary product, Cyrus Bench, is offered as a modified version of the open-source Rosetta molecular modeling tool. This is bundled with essential bio-molecular computation resources, including BLAST, and features a custom user interface to support full utilization.

Who are the top competitors of Cyrus Biotechnology?

Cyrus Biotechnology's top competitors include Vividion Therapeutics, Biognosys and NiKang Therapeutics.

What products or services does Cyrus Biotechnology offer?

Cyrus Biotechnology offers IdeS, IL-22 Variant, and sACE2.v2-Fc.

How many acquisitions has Cyrus Biotechnology made?

Cyrus Biotechnology has made 1 acquisition, including Orthogonal Biologics.

Who are Cyrus Biotechnology's investors?

Cyrus Biotechnology has 11 investors. Key investors include HHS, Orbimed, Trinity Ventures, Agent Capital, and Alumni Ventures.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available